Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period

Gerhard Pölzl1*, Shadab Allipour Birgani1, Josep Comín-Colet2, Juan F. Delgado3, Francesco Fedele4, Martín Jesús García-Gonzáles5, Finn Gustafsson6, Josep Masip7,8, Zoltán Papp9, Stefan Störk10, Hanno Ulmer11, Bojan Vrtovec12, Gerhard Wikström13 and Johann Altenberger14

1Department of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria; 2Department of Cardiology, Bellvitge University Hospital and IDIBELL, University of Barcelona Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 3Department of Cardiology, University Hospital 12 de Octubre, CIBERCV, Madrid, Spain; 4Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Rome, Italy; 5Department of Cardiology, University Hospital Canarias, San Cristóbal de La Laguna, Tenerife, Spain; 6Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 7Intensive Care Department, Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain; 8Cardiology Department, Hospital Sanitas CIMA, Barcelona, Spain; 9Department of Cardiology, Division of Clinical Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; 10Department of Internal Medicine and Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany; 11Department for Medical Statistics, Informatics and Health Economics, Medical University Innsbruck, Innsbruck, Austria; 12Department of Cardiology, University Medical Center Ljubljana, Ljubljana, Slovenia; 13Department of Cardiology, Institute of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden; 14Cardiac Rehabilitation Center Grossgmain, Pensionsversicherungsanstalt, Teaching Hospital of Paracelsus Medical Private University, Salzburg, Austria

Abstract

Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and with associated healthcare costs and an increased mortality risk. However, few if any major medical innovations have been witnessed in this area in recent times. Levosimendan is a first-in-class calcium sensitizer and potassium channel opener indicated for the management of acute HF. Experience in several clinical studies has indicated that administration of intravenous levosimendan in intermittent cycles may reduce hospitalization and mortality rates in patients with advanced HF; however, none of those trials were designed or powered to give conclusive insights into that possibility. This paper describes the rationale and protocol of LeoDOR (levosimendan infusions for patients with advanced chronic heart failure), a randomized, double-blind, placebo-controlled, international, multicentre trial that will explore the efficacy and safety of intermittent levosimendan therapy, in addition to optimized standard therapy, in patients following hospitalization for acute HF. Salient features of LeoDOR include the use of two treatment regimens, in order to evaluate the effects of different schedules and doses of levosimendan during a 12 week treatment phase, and the use of a global rank primary endpoint, in which all patients are ranked across three hierarchical groups ranging from time to death or urgent heart transplantation or implantation of a ventricular assist device to time to rehospitalization and, lastly, time-averaged proportional change in N-terminal pro-brain natriuretic peptide. Secondary endpoints include changes in HF symptoms and functional status at 14 weeks.

Keywords Levosimendan; Advanced heart failure; Randomized controlled trial; Hospitalization; N-terminal pro-brain natriuretic peptide; Global rank endpoint

Received: 8 May 2018; Revised: 16 July 2018; Accepted: 30 August 2018
*Correspondence to: Gerhard Pölzl, Department of Internal Medicine III, Medical University Innsbruck, Innsbruck 6020, Austria. Tel: +43 512 504 81318; Fax: +43 512 504 23264.
Email: gerhard.poelzl@tirol-kliniken.at

Introduction

Heart failure (HF) is the leading cause of adult hospitalization in the industrialized world and imposes a substantial burden on public health. Healthcare costs for HF patients are high and rising, driven by an increase in hospitalizations related to HF. Over recent decades, adoption of evidence-based therapies has reduced the event rate in patients with chronic HF. However, the therapeutic approach for hospitalized patients with acute HF has remained practically unchanged,
and outcomes for these patients are still poor\textsuperscript{4,5}: hospitalization for acute HF is associated with higher mortality, recurrent hospitalization, and increased resource consumption.\textsuperscript{4,6} In a European survey, 1 year mortality was 23.6\% for individuals hospitalized with acute HF, compared with 6.4\% for outpatients with chronic HF.\textsuperscript{4} The majority of rehospitalizations occur early after hospital discharge: about a quarter of patients are rehospitalized within the first month and two-thirds within 1 year.\textsuperscript{2,7}

Strategies to prevent rehospitalizations during this vulnerable period have not been consistently successful so far, although adherence to well-established medical therapies at optimal doses is considered essential.\textsuperscript{5} Recently, sacubitril/valsartan,\textsuperscript{8} ivabradine,\textsuperscript{9} and cardiac resynchronization therapy\textsuperscript{10} were found to reduce both hospitalizations and rehospitalizations. Intermittent or continuous inotropic therapy has also been tested, but, despite favourable haemodynamic and symptomatic improvement in pilot trials,\textsuperscript{11} no positive effect on hospitalizations has been observed, and, in fact, there has been a trend towards a higher mortality risk.\textsuperscript{12}

Levosimendan, a calcium sensitizer and potassium channel opener, is indicated for acute HF. The compound has an active metabolite (OR1896) that prolongs its effects beyond the infusion period.\textsuperscript{13} The theoretical advantages of levosimendan in comparison with traditional inotropic agents include (i) a lack of increase in intracellular calcium concentration and thus no increase in myocardial oxygen demand; (ii) prolonged effects via the formation of an active metabolite; (iii) beneficial symptomatic, neurohormonal, and haemodynamic effects (e.g. decrease in pulmonary capillary wedge pressure and increase in cardiac output); (iv) no attenuation of effect in patients using beta-blockers; and (v) beneficial effects on renal function and peripheral organ perfusion.\textsuperscript{14} Several clinical studies of the repetitive use of intravenous (i.v.) levosimendan have suggested that such a strategy may benefit patients with advanced HF by reducing hospitalization and mortality.\textsuperscript{15–17} However, some of these studies were open-label, single-centre studies, and even the largest, double-blind trial performed to date—LevoRep (NCT01065194)\textsuperscript{17}—was limited to 120 patients. Therefore, a larger study is needed to verify these favourable preliminary results.\textsuperscript{18,19}

In this paper, the design of the randomized, double-blind, placebo-controlled LeoDOR (levosimendan infusions for patients with advanced chronic heart failure) trial is presented. This study will assess the efficacy and safety of intermittent levosimendan therapy started during the vulnerable phase following a hospitalization for acute HF. The overarching hypothesis is that, compared with placebo, repetitive administration of levosimendan during the post-acute phase will be associated with greater clinical stability over a follow-up period of 14 weeks.

**Study design**

The LeoDOR (Figure 1) is a multicentre, randomized, double-blind, placebo-controlled, three-arm trial designed to evaluate the efficacy and safety of intermittent levosimendan therapy, administered in addition to standard therapy for a period of 12 weeks either as a 6 h continuous infusion at a rate of 0.2 \( \mu \text{g/kg/min} \) every 2 weeks or as a 24 h continuous infusion at a rate of 0.1 \( \mu \text{g/kg/min} \) every 3 weeks. The primary endpoint will be evaluated after 14 weeks. Another follow-up visit to obtain information on safety events is scheduled after 6 months. The study intends to include 264 patients in 28 centres in nine European countries.

Appraisal of levosimendan efficacy in LeoDOR is based on a hierarchical composite outcome. The primary efficacy assessment will be made using a global rank endpoint in which all participants are ranked across three hierarchical groups: (i) time to death or urgent heart transplantation or...
implantation of a ventricular assist device (VAD); (ii) time to non-fatal HF requiring i.v. vasoactive therapy; and (iii) time-averaged proportional change in N-terminal pro-brain natriuretic peptide (NT-proBNP) from baseline to Week 14 with (i) as the most important event. Secondary efficacy endpoints include individual components of the primary endpoint at short-term (14 weeks) and intermediate-term (26 weeks) follow-up, as well as changes in functional status.

The LeoDOR Executive Committee (Appendix) designed the trial and wrote the study protocol. The protocol was approved by the Ethics Review Committee/Institutional Review Board affiliated to each centre, and the study will be conducted in accordance with Good Clinical Practice and the 2002 Declaration of Helsinki. All participants will provide written informed consent prior to any study-related investigations. The trial has been registered at https://clinicaltrials.gov, NCT03437226.

**Study population and inclusion/exclusion criteria**

The study population will include male and female patients aged ≥18 years hospitalized for an acute HF event requiring i.v. diuretics, i.v. vasodilators, i.v. inotropic therapy, or any combination of those interventions. Patients must have had a diagnosis of chronic HF for ≥6 months prior to screening and must have been treated with individually optimized long-term therapies for ≥1 month preceding the index hospitalization. Further inclusion criteria are left ventricular ejection fraction ≤30% assessed during index hospitalization, at least one previous hospitalization or visit to an outpatient clinic for acute decompensated HF within the 12 months before the index hospitalization and either NT-proBNP levels (as measured by the local laboratory) after recompensation of ≥2500 ng/L (BNP ≥900 ng/L) or persistent New York Heart Association functional class III or IV at study entry. Patients are considered recompensated and ready for discharge when haemodynamically stable, euvolemic, established on evidence-based oral medication, and with stable renal function for at least 24 h.20 Patients with severe obstruction of the ventricular outflow tract, severely impaired ventricular filling such as restrictive cardiomyopathy, predominantly right-sided HF and/or severe tricuspid regurgitation, cardiac surgery, coronary angioplasty, or acute coronary syndromes within 30 days of initiation of study drug are not eligible. Further exclusion criteria include patients scheduled for cardiac surgery or angioplasty within the next 3 months; history of torsades de pointes; stroke or transient ischaemic attack within 3 months of initiation of study drug; systolic blood pressure <90 mmHg or heart rate ≥120 beats/min at baseline; serum potassium <3.5 mmol/L before initiation of study drug; estimated glomerular filtration rate <30 mL/min/1.73 m²; haemoglobin <10 g/dL; significant hepatic impairment; hypersensitivity to levosimendan; other serious diseases that considerably limit life expectancy; pregnancy or lactation; and administration of levosimendan within 14 days of initiation of study drug (Table 1).

**Table 1** LeoDOR inclusion and selected exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male and female patients aged &gt;18 years</td>
<td>Severe obstruction of ventricular outflow tracts, such as haemodynamically significant uncorrected primary valve disease or hypertrophic cardiomyopathy or impaired ventricular filling, such as restrictive cardiomyopathy</td>
</tr>
<tr>
<td>HF diagnosed at least 6 months before screening and treated with individually optimized long-term oral and device treatment for the last month, unless not tolerated</td>
<td>Predominantly right-sided heart failure and/or severe tricuspid regurgitation</td>
</tr>
<tr>
<td>LVEF ≤30% as assessed using echocardiography, radionuclide ventriculography, or contrast angiography during the index hospitalization</td>
<td>Cardiac surgery or coronary angioplasty within 30 days prior to study drug initiation</td>
</tr>
<tr>
<td>Patients previously hospitalized for decompensated HF requiring i.v. diuretics or i.v. vasodilators or i.v. inotropic therapy</td>
<td>Acute coronary syndromes within 30 days prior to study drug initiation</td>
</tr>
<tr>
<td>Previous hospitalization or visit to an outpatient clinic requiring i.v. diuretics, i.v. vasodilators, or i.v. inotropic therapy for acute decompensated HF within 12 months prior to index hospitalization</td>
<td>Patients scheduled for cardiac surgery or angioplasty within the next 3 months</td>
</tr>
<tr>
<td>NT-proBNP level (as measured by the local laboratory) after recompensation of ≥2500 ng/L and/or NYHA class III or IV at study entry. A compensated status is reached when the patient is haemodynamically stable, euvolemic, established on evidence-based oral medication, and with stable renal function for at least 24 h</td>
<td>History of torsades de pointes</td>
</tr>
<tr>
<td>Heart rate ≥120 beats/min at baseline</td>
<td>Heart rate &gt;120 beats/min at baseline</td>
</tr>
<tr>
<td>Serum potassium &lt;3.5 mmol/L before study drug initiation</td>
<td>Serum potassium &lt;3.5 mmol/L or after initiation of study drug initiation</td>
</tr>
<tr>
<td>eGFR ≤30 mL/min/1.73 m²</td>
<td>eGFR ≥30 mL/min/1.73 m²</td>
</tr>
<tr>
<td>Administration of levosimendan within 14 days prior to study drug initiation (first study drug application to be postponed for at least 14 days after the end of this premedication)</td>
<td>Administration of levosimendan within 14 days prior to study drug initiation</td>
</tr>
<tr>
<td>Hypersensitivity to levosimendan</td>
<td>Hypersensitivity to levosimendan</td>
</tr>
<tr>
<td>Other serious diseases that considerably limit life expectancy (e.g. end-stage cancer, end-stage renal disease, and end-stage lung disease)</td>
<td>Other serious diseases that considerably limit life expectancy</td>
</tr>
</tbody>
</table>

eGFR, estimated glomerular filtration rate; HF, heart failure; i.v., intravenous; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.
Patients will be randomized after recompensation from the index episode of acute HF. Randomization can take place either at the end of the hospital stay or within 14 days after discharge for the index hospitalization.

**Study treatment**

Candidates for the study will be screened during hospitalization for acute decompensated HF. During the first treatment visit, eligibility for the trial will be confirmed, the patient will be randomized, and the first infusion of the study drug will be administered. The first treatment visit should preferentially be scheduled during the index hospitalization or, at the latest, within 14 days after discharge from hospital. If the baseline visit takes place during the index hospitalization, the patient’s condition should be stabilized so as to facilitate administration of the study drug on the last day of the index hospitalization.

Levosimendan or matching placebo will be administered as an i.v. infusion. For the 6 h infusion group, the study drug will be administered at a continuous infusion rate of 0.2 μg/kg/min for 6 h. The scheduled study drug administrations will take place on Day 0, Day 14 (±2 days), Day 28 (±2 days), Day 42 (±2 days), Day 56 (±2 days), Day 70 (±2 days), and Day 84 (±2 days). For the 24 h infusion group, the study drug will be administered at a continuous infusion rate of 0.1 μg/kg/min for 24 h. The scheduled study drug administrations will take place on Day 0, Day 21 (±3 days), Day 42 (±3 days), Day 63 (±3 days), and Day 84 (±3 days) (Figure 1).

At Day 84, the study medication will be stopped for all patients; a follow-up visit will be arranged for 14 days (±2 days) after cessation of treatment. A second follow-up visit will be arranged at 180 days (±14 days) after initiation of study medication.

**Study assessments**

Components of the primary endpoint, which comprises death, urgent heart transplantation or VAD implantation, as well as non-fatal acute HF events, will be reported from receipt of completed patient informed consent forms until Week 26. All reported events will be adjudicated by the Endpoint Adjudication Committee (Appendix).

A ‘non-fatal acute HF event’ is defined as presentation of the patient for an urgent, unscheduled visit at a clinic, office, emergency department, or hospital with a primary diagnosis of HF, i.e. where the patient exhibits new or worsening symptoms of HF on presentation, has objective evidence of new or worsening HF, and receives i.v. vasoactive therapy, defined according to Hicks et al. 21 as i.v. diuretics, i.v. vasodilators, i.v. inotropes, or any combination of those interventions.

N-terminal pro-brain natriuretic peptide will be assessed at baseline and at Weeks 6, 12, and 14. Biomaterials will be shipped to and stored and analysed at the Interdisciplinary Bank of Biomaterials and Data, University of Würzburg.

Symptoms and functional status will be assessed at baseline and at Week 14 using the following instruments: (i) the Kansas City Cardiomyopathy Questionnaire, a self-administered, 23-item questionnaire that quantifies physical limitation and quality of life in patients with HF. 22 Changes in clinical summary score will be used for analyses; (ii) the 6 min walk test conducted according to the guidelines for the six-minute walk test published by the American Thoracic Society 23; and (iii) New York Heart Association HF classification recorded by the investigator.

The seven-item patient’s global assessment (PGA) is scheduled to take place at Week 14 after beginning administration of the study drug and will be conducted before any other assessment, interview, or study drug administration, so that the answers will not be influenced by the study procedures. 24 For patients hospitalized for any reason by the planned date of the PGA, every effort will be made to conduct it. If the PGA cannot be performed in a hospital, the patient will be categorized as ‘hospitalized’ and ranked under the category ‘much worse’. Patients who die on or before the planned date of PGA will be categorized as ‘died’ and ranked under the category ‘hospitalized’.

Cost-effectiveness will be assessed using the five-level version of the EuroQol EQ-5D questionnaire, which will be completed by the patient at baseline and Week 14. 25

**Endpoint selection**

**Primary endpoint**

The primary efficacy objective of the study is to compare the effects of pulsed application of levosimendan versus placebo in patients with advanced chronic heart failure during a vulnerable period of 14 weeks following a recent hospitalisation on a global rank endpoint, in which all participants are ranked across three hierarchical groups (in ascending order):

- time to death or urgent heart transplantation or implantation of a VAD;
- time to a non-fatal HF event requiring i.v. vasoactive therapy (i.v. diuretics, i.v. vasodilators, or i.v. inotropes); and
- time-averaged proportional change in NT-proBNP from baseline to 14 weeks.

**Secondary endpoints**

The secondary efficacy objectives are to determine the effects of pulsed application of levosimendan on the individual components of the primary endpoint at 14 and 26 weeks (time-averaged proportional change in NT-proBNP will be determined from baseline to 14 weeks only), plus changes in
Symptoms and functional status at 14 weeks and the cumulative number of acute HF events and cumulative days alive and out of hospital at 14 and 26 weeks.

Additional study objectives are to determine the effects of pulsed application of levosimendan on changes in background medication and biomarkers, as well as cost-effectiveness.

**Statistical considerations and randomization**

The statistical hypothesis is that, compared with placebo, levosimendan in patients with advanced HF will be associated with greater clinical stability as assessed using a global rank endpoint, which is a composite of (i) time to death or urgent heart transplantation or VAD implantation, (ii) time to a non-fatal HF event requiring i.v. vasoactive therapy, and (iii) time-averaged proportional change in NT-proBNP from baseline to 14 weeks. Patients will be ranked so that those who meet component (i) will get the lowest rank starting with Rank 1 for the patient with the earliest endpoint. Thereafter, patients meeting component (ii) will be ranked similarly, where the patient with the earliest endpoint is ranked the number of deaths plus 1. Finally, patients who do not meet components (i) or (ii) will be ranked so that those who respond best (i.e. who have the largest decline in NT-proBNP) will get the highest rank (equal to sample size).

Statistical assumptions of rates of death and acute HF events in the placebo group (10% and 30%, respectively) are based on data from Gheorghiade et al., Cowie et al., and OPTIME-CHF. Effect-size assumptions for repetitive levosimendan treatment (20% relative risk reduction for death and acute HF) are derived from experience in the LevoRep, LionHeart, and LAICA (NCT00988806; unpublished data, from personal communication with Martín Jesús García-Gonzáles) trials.

Assuming a total of 264 patients (6 h infusion group: levosimendan, n = 88; placebo, n = 44; 24 h infusion group: levosimendan, n = 88; placebo, n = 44), LeoDOR has ≥90% simulated power to detect a difference between the pooled levosimendan and placebo groups at a two-sided significance level of 5% using the Wilcoxon–Mann–Whitney test. Using the same simulation model, the individual components of the global rank endpoint (death, acute HF, and ΔNT-proBNP) have ≥10%, ≥20%, and ≥99% power, respectively, to detect a difference between groups.

The intention-to-treat data set including all randomized patients will be used for the primary evaluation. Sensitivity analyses using the per-protocol data set will be considered and will be described in the statistical analysis plan should a meaningful number of patients exhibit major protocol violations. All patients who receive any study treatment will be included in the safety evaluation.

Patients will be randomized to receive either levosimendan or matching placebo in a ratio of 2:1. Clinical effect is assumed to be similar between the two infusion schedules, and the statistical hypothesis will compare the pooled levosimendan contingent with the pooled placebo group. Of note, the infusion schedule (6 or 24 h) is not part of the randomization or stratification scheme; the infusion group will be selected based on centre preference or convenience for the patient. Randomization will be balanced at each centre using randomly permuted blocks specific for each centre and infusion group.

**Study schedule**

The first patients will be enrolled in LeoDOR in February 2018. The recruitment period will last for 16 months until June 2019. Study completion is anticipated in February 2020.

**Discussion**

The aim of the LeoDOR trial is to investigate efficacy and safety of intermittent levosimendan therapy during the vulnerable phase after a recent hospitalization for acute HF in advanced HFREF patients.

Hospitalization for the management of acute decompensation is a sentinel event in the trajectory of HF and one that has important prognostic implications. Readmission and mortality rates are particularly high during the 3 month period after discharge. Rehospitalizations during this early discharge period, which is also known as the ‘vulnerable phase’, account for a disproportionate amount of the extensive overall costs of HF care. Although up to 75% of early readmissions may be preventable, effective measures to prevent rehospitalizations during this vulnerable period remain ill defined.

Recent meta-analyses suggest that repetitive levosimendan may reduce hospitalization and mortality in patients with advanced HF. Individual studies, including the LevoREP trial, were, however, underpowered to provide definite conclusions regarding these endpoints. Accordingly, the LeoDOR trial is powered to compare the effects of repetitive administration of levosimendan vs. placebo during the vulnerable post-discharge period following hospital admission for acute HF using a hierarchical composite endpoint including death and rehospitalization. Efficacy will be tested 14 weeks after the first infusion; a safety endpoint including death and hospitalization is scheduled for 12 weeks after the first infusion.

**Rationale for study design and endpoint selection**

Outpatient therapy and management is highly desirable for patients with advanced HF and compromised quality of life, which is often related to repeat HF-related hospitalizations. In this context, repetitive infusions of levosimendan in an ambulatory setting appear promising. Such a strategy is safe, as evidenced by the LevoRep and LionHEART. The LeoDOR...
trial will follow this concept. A second active-treatment study arm with a 24 h continuous infusion of levosimendan is included to meet the infrastructural and economic requirements of countries and centres that currently do not support ambulatory therapy in advanced HF. To achieve comparable cumulative drug doses in both treatment arms, the dosage per hour (0.2 vs. 0.1 µg/kg/min) and the number of infusions (seven vs. five repetitions) will be higher in the 6 h arm compared with the 24 h arm. Patients will be allocated to levosimendan or placebo in a ratio of 2:1.

Endpoint selection for high-risk HF populations is critical and is often the subject of debate. The main clinical targets are to relieve symptoms, to reduce the number and length of hospitalizations, and, ultimately, to reduce mortality. Symptomatic improvement has turned out to be a problematic endpoint in HF trials as confounding factors may influence its reliable measurement. A composite endpoint comprising mortality and hospitalizations would potentially have wide acceptance. However, this approach might create substantial problems in interpreting trial results as both components of the composite would be treated equally, despite the fact that clinicians and patients may attach different values to the specific components. Furthermore, thresholds for hospitalization vary substantially between institutions and countries, and hospitalizations tend to occur more frequently than mortality events and therefore have a greater effect on the endpoint. This applies particularly when a ‘time-to-event’ method is used, where patients are followed up until the first event of the composite endpoint. Furthermore, the components of the composite may ‘move’ in different directions, which can further complicate coherent interpretation of the study results. Finally, restricting the combined endpoint to mortality and hospitalization requires a substantially large sample size and/or a considerably long follow-up period.

An approach that assigns proper weight to different outcomes and also enables every patient to contribute to the endpoint would optimize the feasibility of a study, without compromising the clinical impact that may be derived from trial results.

A study in advanced HF with a primary endpoint combining death, rehospitalization, and positive neurohormonal response has been published recently. Each patient was assigned a global rank score based on their outcomes during follow-up. The components were analysed in a hierarchical manner so that deaths were the most important events, followed by rehospitalizations and, finally, effect on NT-proBNP. No statistically resilient treatment effect was demonstrated in that study, but the credibility of the outcome-ranking methodology was demonstrated.

The LeoDOR will apply a similar endpoint methodology for the assessment of repetitive cycles of levosimendan in the management of patients who have experienced a recent hospitalization for acutely decompensated HF. Adding changes in NT-proBNP over time as an additional component also allows a more comprehensive interpretation of the effects of the study drug on the complex trajectory after discharge. As shown recently, follow-up BNP level and per cent change in BNP within 3 months after discharge were predictors of long-term mortality but were also superior to BNP levels on hospital admission.

In summary, the LeoDOR trial will test efficacy and safety of intermittent levosimendan therapy in patients with ‘very’ advanced but not acute HF with the highest short-term and long-term mortality and rehospitalization rates.

Perspective

The concept of pulsed administration of levosimendan for patients with advanced HF during the vulnerable phase after a recent hospitalization for acute HF, as will be tested in the LeoDOR trial, potentially represents an important contribution to the therapeutic armamentarium for such patients. In particular, the study is configured to examine evidence of efficacy of an intensified therapy using clinically relevant endpoints for severely ill patients managed on an outpatient basis.

Conflict of interest


Funding

The LeoDOR study is supported by an unrestricted grant from Orion Pharma, the manufacturer of levosimendan. Orion Pharma is not involved in data management, assessment of endpoints, and analysis or publication of the LeoDOR trial.

Appendix

Sponsor: Medical University of Innsbruck.

Principal investigator: G. Pölzl, Department of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Steering committee: J. Comin-Colet, Spain; J.F. Delgado, Spain; F. Fedele, Italy; M.J. Gonzales, Spain; F. Gustafsson, Denmark; J. Masip, Spain; Z. Papp, Hungary; G. Pölzl, Austria; S. Störk, Germany; G. Wikström, Sweden; B. Vrtovec, Slovenia.

Executive committee: J. Altenberger, Austria; M. Kivikko, Finland; G. Pölzl, Austria; P. Pollesello, Finland; T. Sarapohja, Finland; S. Störk, Germany; H. Ulmer, Austria.

DOI: 10.1002/ehf2.12366
Data monitoring committee: C. Adelbrecht, Austria; J. Bauersachs, Germany; F. Hintringer, Austria; R. Matteucci Gothe, Austria; P. Mohacsi, Switzerland.

Endpoint adjudication committee: H.P. Brunner-La Rocca, the Netherlands; S. Frantz, Germany; T. Suter, Switzerland.

References


ESC Heart Fail 2019; 6: 174–181
DOI: 10.1002/ehf2.12366


